BioMarin Pharmaceutical
From Wikipedia, the free encyclopedia
BioMarin Pharmaceutical (NASDAQ: BMRN) is a biotechnology firm based in Novato, California. It has offices and facilities in both the US, South America and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin is the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing Aldurazyme (commercialized by Genzyme Corporation). BioMarin is also the first company to provide therapeutics for Phenylketonuria (PKU)
As of 2005, BioMarin commercialized arylsulfatase B (Naglazyme) as an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), and in 2007 a drug version of tetrahydrobiopterin (Kuvan), the first medication-based intervention to treat phenylketonuria.[1]
[edit] References
- ^ Pollack, A. "Agency Approves Drug to Treat Genetic Disorder That Can Lead to Retardation", The New York Times, 2007-12-14. Retrieved on 2008-04-03.
[edit] External links
 |
This biotechnology article is a stub. You can help Wikipedia by expanding it. |
This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
